CagriSema

No brand yet · Novo Nordisk. Semaglutide plus cagrilintide, a long-acting amylin. Would be the first amylin-based obesity medicine. FDA decision expected in Q4 2026.

Average weight loss

22.7%

Stopped for side effects

Trial length

68 wk

Ranking score

5.2

REDEFINE 1 results

Phase 3 · 68 weeks · 2.4 mg cagrilintide + 2.4 mg semaglutide
Adults with obesity, no diabetes (n=3,417)

Weight loss

22.7%

Nausea

55.0%

Vomiting

26.1%

Diarrhea

n/r

Constipation

30.7%

Quit due to side effects

6.0%

n/r = not reported. Counting everyone who started, weight loss was 20.4%. Placebo group: 2.3%.

Worth knowing

Missed its goal against tirzepatide in the head-to-head REDEFINE 4 trial.
Diarrhea rate not published in sources we could verify; scored on 3 of 4 stomach measures.

Next catalysts

Q4 2026 FDA decision on CagriSema for obesity (Company guidance)

5.2

GLP-1 Performance Index

Rank 3 of 6 ranked drugs

Stomach = (55.0 + 26.1 + 30.7) ÷ 3 = 37.3 Burden = 37.3 + 1 × 6.0 = 43.3 Index = 22.7 ÷ 43.3 × 10 = 5.25

Scored on 3 of 4 stomach measures; one rate is not published.

At a glance

Company: Novo Nordisk
Targets: Amylin, GLP-1
Molecule: Peptide
Dosing: Injection, weekly
Status: Under FDA review

Compare with another drug

Sources

History

Sep 30, 2026
CagriSema: new EASD data on food cravings and liver fat; FDA decision still expected Q4 2026.